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COST OF CARING PATIENTS WITH COLORECTAL CANCER WITH
CAPECITABINE VS 5-FU BASED REGIMENS: PRELIMINARY
RESULTS OF A NATURALISTIC STUDY
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1CIRFF, Federico II University of Naples, Naples, 2Fondazione CHARTA, Milan,
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A.O.R.N.A. Cardarelli, Naples, Italy
Introduction and aim: Colorectal cancer (CRC), the third most prevalent cancer
worldwide, imposes a significant economic and humanistic burden on patients and
society. The aim of this analysis was to evaluate the cost of capecitabine vs conventional
strategies (5-FU) for the treatment of metastatic CRC in Italy.
Methods: The study was a naturalistic, multicentre, retrospective longitudinal cost of
care (COC) analysis. The study included subjects enrolled from 3 centres. Direct
healthcare resources attributable to CRC treatment (drugs, ambulatory care,
hospitalisations, diagnostics and laboratory exams) were quantified using prices or
tariffs expressed in Euro 2005, as appropriate. The analysis was conducted from the
National Health Service (NHS) perspective with a 6 month time horizon. Difference in
the COC between capecitabine and 5-FU based regimens was tested using Mann–
Whitney U test.
Results: A total of 197 (5-FU 99, Capecitabine 98) patients affected by CRC (55.3%
male; mean age 63.9 ± 10.1 y.o.) were studied. Total direct cost per patients per month
in Capecitabine and 5-FU group were 982 (±419) and 3,265 (±1,025) Euro respectively
(P < 0.0001).
Discussion: CRC imposes significant burden to the NHS and total direct cost of
Capecitabine is significantly lower compared to 5-FU.
SAFETY AND CONVENIENCE OF CETUXIMAB (CET) AND
IRINOTECAN (IRI) BOTH GIVEN EVERY TWO WEEKS IN METASTATIC
COLORECTAL CANCER (MCRC) PATIENTS (PTS). PRELIMINARY
REPORT
Colina P, Antonelli G, D’Angelo A, Giamo V, Priolo D & Ferraù F
Division of Medical Oncology, ‘S. Vincenzo’ Hospital, Taormina, Italy
The anti-EGFR monoclonal antibody CET is active in IRI-treated mCRC pts, in
combination with IRI in a standard weekly timing of administration. Searching for
a more practical schedule and following previous reports [1], we decided to test the
safety of a more convenient every 2 weeks (q2w) schedule of combination of CET and
IRI.
Pts and methods: From 09/2006 to 02/2007 we have treated 14 pts with histologically
confirmed, EGFR-expressing, mCRC with ‡1 bi-dimensionally measurable lesion,
ECOG PS £2, adequate bone marrow, renal, and hepatic functionality; PS 0–1, M/F:
8/6, median age 54 yrs (range 48–71). All pts were previously treated at least with IRI
(FOLFIRI or IRI monotherapy) for metastatic disease. Prevalent sites of disease were
liver (10 pts) and lung; median number of previous treatment was 2.5 (range 2–4). CET
was given q2w at the dose of 400 mg/m2 and IRI q2w at dose of 180 mg/m2;
instrumental evaluation was done every two months. A total of 41 cycles (cy) were
administered (range 3–10, median 5/pts). The most frequent non haematological
toxicity was the skin reaction, globally mild: G1–2: 56% of cy, 6 pts; G3: 12%, 2 pts;
none G4. Diarrhoea (G3: 22% cy), vomiting (G3: 17% cy), alopecia (G3: 33%) were
superimposable to that of traditional weekly schedule of CET + IRI. Haematological
toxicity was also moderate: neutropenia G3 in 25% of cy, anaemia in 18%, PLT-penia
in 7%. Globally the compliance of this treatment schedule resulted very high: only 8 cy
(17%) were delayed due to gastrointestinal symptoms (5 cy) or neutropenia (3). In
summary, CET given q2w in combination with q2w IRI may be a feasible and more
convenient schedule of administration. Further experiences will elucidate the possible
role of higher doses of CET and the response rate of this modified schedule.
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Introduction: Many evidences show that there is a significant different distribution
into age, gender, tumor progression and response to adjuvant treatment in patients
with colon and rectal cancers, which have genetic differences between themselves. For
example, it is demonstrated that Ki-RAS mutations are more commonly detected in
colon than in rectal cancers.
Methods: To verify Ki-RAS mutations in rectal cancer, a series of 42 alcohol fixed-
paraffin embedded stage I (No) primary rectal cancer and respective regional multiple
lymph nodes were deparaffined, stained with hematoxylin–eosin and microdissected
through LPC. Then they were analyzed through PCR, SSCP and direct sequencing of
Ki-RAS mutations.
Results: Six of 42 (14%) of primary tumors analyzed showed a Ki-RAS missense
mutation in codon 12 or 13 in exon 2. In 50% (3/6), the mutation was GGT/GAT
(Gly/Asp) in codon 12, and the other 50% (3/6) was a GGC/GCC (Gly/Ala) in
codon 13. In all cases, the same mutations were confirmed in the respective lymph
nodes.
Conclusion: In this work we show that the percentage of Ki-RAS mutations in codons
12 and 13 in rectal cancer are sensibly lower than in colon cancer, providing further
evidence that these two kinds of tumors should be considered two different entities.
Moreover, we show that the detection in regional lymph nodes of the same mutation of
primary tumor might represent an indicator of lymph nodes metastasis in rectal
carcinoma not detected in routine histologic examination.
BEVACIZUMAB 1 FOLFIRI AS FIRST-LINE THERAPY IN ADVANCED
COLORECTAL CANCER: A MULTICENTER PHASE II STUDY OF THE
GRUPPO ONCOLOGICO DELL’ ITALIA MERIDIONALE (PROT. GOIM
2601)
Giuliani F1, De Vita F2, Lorusso V3, Maiello E4, Orditura M2, Nugnes I1, Leo S4,
Catalano G2 & Colucci G1
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Background: In a randomised phase III trial, the addition of Bevacizumab (Bev) to
Irinotecan (Cpt-11) plus bolus Fluorouracil (FU) and Folinic Acid (FA) (IFL regimen)
demonstrated to be more active than chemotherapy alone in untreated advanced
colorectal cancer (ACC) patients [1]. The bolus administration of FU-FA is considered
inferior to infusional regimen in terms of activity and toxicity. So we started
a multicenter phase II study to evaluate the activity and safety of the combination of
Bev plus FOLFIRI regimen as first line therapy in ACC patients.
Methods: Untreated patients with histologically/citologically confirmed diagnosis of
colorectal cancer entered into the trial if they satisfied the following main inclusion
criteria: presence of measurable disease, age ‡18 yrs, performance status £2 (ECOG
scale), adequate bone marrow reserve and renal and hepatic function, informed written
consent. Clinically significant cardiovascular disease and thromboembolic disorders
were considered exclusion criteria. The enrolled patients received: Cpt-11 at 180 mg/m2
on day 1, FA at 100 mg/m2 as 2 h infusion on days 1–2, FU at 400 mg/m2 as bolus on
days 1–2 plus FU at 600 mg/m2 as 22 h infusion on days 1–2 (FOLFIRI) plus Bev
administered at the dosage of 5 mg/kg. The cycles were repeated every 2 weeks. The first
evaluation of activity (RECIST criteria) was performed after 4 cycles.
Results: Up to now 38 patients have been enrolled and 31 are evaluable for activity and
toxicity. The main characteristics of the evaluable patients are: M/F 16/15; median PS:
1; primary site (C/R) 20/11; sites of disease: liver 19, lung 11, lymph nodes 8, others 5;
single/multiple sites 18/13 (58%/42%). Sixteen PR (52%), 10 SD (32%) and 4 PRO
(16%) were observed for an ORR of 52% and a TGCR of 84%. The only grade 3–4 (NCI
criteria) toxicities were: neutropenia 16% and thrombocytopenia 3%; five patients
(16%) had hypertension but only one was uncontrolled by medical therapy and
interrupted the study. One patient (3%) had epistaxis.
Conclusions: Our preliminary results indicate that the addition of Bev to FOLFIRI
regimen is an active and well tolerated first-line treatment of ACC patients. The study is
ongoing.
BONE MARROW INVOLVEMENT IN ADVANCED COLORECTAL
CANCER: A CASE REPORT
Morelli F, Palomba G, Aieta M, Di Micco C, Boni V & Maiello E
Oncology Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo,
Italy
Introduction: The haematopoietic dysfunction in cancer patients represents a widely
disparate group of clinical conditions. A diffuse marrow involvement usually occurs at
the terminal stage of cancer and is extremely rare as an initial presentation in patients
with cancer. Recently, a survey [1] reported in 46 adult age cases, bone marrow
metastasis. Primary tumours of this series were as follows: prostate 22 cases, breast 13,
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Materials and methods: A 64 year old man with no previous significant medical
problems presented to our Institution with one month long history of low back and left
hip pain, and intermittent mild abdominal pain. Remarkable laboratory findings were
platelets = 24.000 ll and D-Dimers = 7000 mg. We suspected a metastatic bone
marrow involvement and therefore a bone marrow aspiration and biopsy were
performed. We documented an extensive marrow infiltration by poorly differentiated
adenocarcinoma (positive immunochemistry for CK 20 and negative for CK 7, TTF 1
and PSA). Chest X rays and abdominal CT scan revealed no abnormality.
Colonfiberscopy found a colon cancer at 10 cm from anal ridge, poorly differentiated
adenocarcinoma with mucus-secreting component in histopathology. Whole body
bone scan revealed increased uptake in multiple sites. Whole spine MRI revealed an
increase of water content due to watery changes of the bone marrow and replacement
of the fat by serous materials.
Results: The patient received combination chemotherapy with oxaliplatin and 5-FU/
LV (FOLFOX 4). Before cytotoxic chemotherapy transfused platelets. Recovery of
blood counts was evident after 1 cycle. A bone marrow aspiration and biopsy
performed after 4 cycles were carried out and revealed normocellular marrow with
focal bone sclerosis without neoplastic involvement. At the time of this report,
6 months from the diagnosis, the patient is alive with a good performance status
and haematologic findings are stable.
Conclusions: When the physician is confronted by a patient with clinical findings of
thrombocytopenia and increased D-Dimers (referred to a disseminated intravascular
coagulation) which often occurs in bone marrow metastasis, he must remain vigilant
for an additional diagnosis such as prostate, breast, lung or gastro-intestinal cancer.
Platelets transfusions coupled with specific treatment of the underlying disease remain
the mainstay of therapy for such extensive marrow infiltrative conditions.
CAPECITABINE IN COMBINATION WITH OXALIPLATIN OR WITH
IRINOTECAN IN ELDERLY PATIENTS WITH ADVANCED
COLORECTAL CANCER: PRELIMINARY RESULTS OF A
RANDOMIZED PHASE II STUDY
Rosati G1, Cordio S2, Bordonaro R3, Gebbia V4, Rinaldi A5, Giannitto G6,
Borsellino N7, Reggiardo G8 & Manzione L1
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Background: Elderly patients (pts) are a special population due to the comorbidities,
the altered drug metabolism and the loss of functional capacity, which are associated to
an increased drug toxicity. Single-agent therapy is a common practice in elderly pts
with advanced colorectal cancer (ACC) and there are not conclusive data in literature
on the combination regimens used in these cases. Capecitabine has demonstrated
comparable efficacy to bolus 5-FU/FA regimens with clinically safety advantages. The
aim of this trial is to evaluate it when combined to oxaliplatin (CAPOX) or irinotecan
(CAPIRI) in elderly pts with ACC.
Patients and methods: Pts ‡70 years (yrs) old with histologically confirmed ACC,
measurable disease, PS 0–2, and adequate renal, hepatic and bone marrow function
were included. Previous chemotherapy for advanced disease, CNS involvement or >3
geriatric syndromes was not allowed. Pts were randomized to receive CAPOX
(oxaliplatin 65 mg/m2 i.v. d1, 8 and capecitabine 1000 mg/m2 orally bid d1–14; q21) or
CAPIRI (irinotecan 80 mg/m2 i.v. d1, 8 and capecitabine 1000 mg/m2 orally bid d1–14;
q21) until progressive disease, unacceptable toxicity or consent withdrawal. Patients
were followed by a geriatric and a quality of life (QoL) assessment with specific scales
and EORTC-QLQ-C30 questionnaire.
Results: Sixty-eight pts (of target 94) were analyzed (37 received CAPOX and 31
CAPIRI). Characteristics: CAPOX: median age 75 yrs (range 70–85); PS: 0/1/2 = 21/15/
1; prior adjuvant therapy: 28.5%; CAPIRI: median age 74 yrs (range 70–85); PS: 0/1/2 =
18/13/0; prior adjuvant therapy: 22.5%. Safety analysis was performed in all analyzed
pts. The most frequent grade 3–4 adverse events were diarrhea (CAPIRI: 19.3%;
CAPOX: 14.2%) and neutropenia (CAPIRI: 22.5%; CAPOX 2.8%). No treatment
related death occurred. Among evaluable pts (26 in CAPIRI and 31 in CAPOX), one
complete response and 9 partial responses were reported in CAPIRI arm (RR: 38.4%);
ten partial responses in CAPOX arm (RR: 32.2%). The median response duration was
8.2 months (range 5–11) for CAPIRI and 6 months (range 4–8.4) for CAPOX. Median
time to progression and overall survival have not been reached.
Conclusions: The employment of capecitabine given in doublet combination is feasible
in the elderly population with ACC. The safety profile of two regimens allows an
evaluation with biological agents. Both combinations are active. Final results will be
presented at the meeting.
PHASE II TRIAL OF A BIWEEKLY REGIMEN OF FLUOROURACIL AND
LEUCOVORIN PLUS IRINOTECAN IN PATIENTS WITH PREVIOUSLY
UNTREATED ADVANCED GASTRIC CANCER
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Introduction: To investigate the therapeutic value and safety of the biweekly regimen
comprehensive of 5-fluorouracil (5-FU) and leucovorin (LV) plus irinotecan (CPT-11)
in patients with previously untreated advanced gastric cancer (AGC).
Patients and methods: A total of 50 patients (M/F 35/15; median age = 65) with AGC,
neither of whom had received chemotherapy for advanced disease, were accrued in this
trial. Fifteen patients (30%) were 70 years old or older. At the time of their accrual,
cytotoxic chemotherapy, consisting of intravenous LV 100 mg/m2 (2-hour infusion)
followed by 5-FU 400 mg/m2 (bolus) and 5-FU 600 mg/m2 (22-hour continuous
infusion) on therapeutic days 1 and 2 plus CPT-11 180 mg/m2 (1-hour infusion) on
day 1, was initiated. Treatment courses were repeated every 2 weeks until evidence of
progressive disease, unacceptable toxicity or withdrawal of consent.
Results: All the patients were assessable for toxicity and 48 out of 50 for response
evaluation, having completed at least four courses of chemotherapy. Complete
response was achieved in 2 patients (4%, intent to treat) and partial response in
16 (32%) [overall response rate, 36%; 95% confidence interval (CI): 22%–50%].
Twenty-four patients (48%) had a stable disease and 6 patients (16%) progressed.
The median time to progression was 8 months (95% CI: 6–10 months) and median
overall survival 14 months (95% CI: 6–22 months). Between the subgroups of patients
<70 years old and 70 or older, there were no significant differences in efficacy. One
toxic death occurred. Treatment tolerance was generally mild to moderate and easy
to treat. The main grade 3/4 toxicities were neutropenia (32%), diarrhea (16%), and
anemia (8%). Grade 3–4 neutropenia was the only treatment-related serious adverse
event significantly more common in patients older than those aged £70
(53.3% vs 22.8%, respectively; P = 0.03).
Conclusions: Our data suggest that the biweekly regimen of LV and 5-FU plus CPT-11
in untreated patients with AGC is active with acceptable safety profile. Further
evaluation of this regimen seems to be warranted in a phase III trial.
ANALYSIS OF TP53, KI-RAS, AND P16INK4A PROMOTER
METHYLATION AS POTENTIAL PROGNOSTIC FACTORS IN
PATIENTS WITH COLORECTAL CANCER
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Background: Colorectal Carcinoma (CRC) is one of the most common solid tumor in
the western world. Despite the improvement in detection and surgical therapy during
last years, the outcome of patients affected by CRC remains limited by metastatic
relapse. A large number of studies conducted on the plasma and serum of patients with
CRC have shown that such subjects have higher levels of circulating DNA fragments
than healthy subjects. The aim of this study was to evaluate the presence of free tumor
DNA in the plasma of CRC patients in order to understand its possible prognostic role.
Material and methods: Ki-Ras, TP53 mutations and P16INK4A methylation status were
analyzed in tumor tissues and plasma of 66 CRC patients. Besides twenty blood sample
of healthy subjects and seven non-neoplastic intestinal tissues were analyzed for the
same alterations as control. The analysis was performed using PCR SSCP techniques for
K-Ras and TP53 and by Methylation Specific PCR (MSP) for the methylation status of
the P16INK4A gene promoter.
Results: In 50/66 primitive tumors (76%) at least one significant alteration was
identified in Ki-Ras and/or TP53 and/or P16INK4A genes. Eighteen of 50 patients
presented the same alteration both in the plasma and in the tumor tissue. No one of
these alterations has been found in the control group. At univariate analysis, Ki-Ras
mutations are related to quicker relapse (P < 0.01), whereas only a trend towards
statistical significance (P = 0.083) was observed for the TP53 mutations.
Conclusion: These data suggest that the detection of circulating tumor DNA using the
analysis of Ki-Ras and TP53 mutational status is a potential tool for early detection of
postoperative CRC recurrence.
MOLECULAR ANALYSIS OF TP53, KI-RAS2 AND P16 METHYLATION
STATUS IN TISSUE AND PLASMA OF SUBJECTS AFFECTED BY
GASTROINTESTINAL CANCER (GIC)
Scolaro L1, Agnese V1, Calò V1, Bruno L1, Augello C1, Cascio S1, Barbera F1,
GarganoG1,Gregorio V1, Calcara D1, La Paglia L1, Schirò V1, Terrasi M1, Fanale D1,
Ferla R1, Fiorentino FP1, Foddai E1, Di Gaudio F2, Graceffa G3, Bazan V1 & Russo A1
1Section of Medical Oncology and 2Section of Oncological Surgery, Department
of Surgery and Oncology, 3Department of Biotechnologies and Legal Medicine,
Università di Palermo, Italy
Introduction: Gastrointestinal Cancer (GIC) is one of the most common leading
cause of cancer-related death in Western society. Despite the advances in the last
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years have resulted in improved outcomes for patients, prognosis remain poor and
limited by metastating relapse. The aim of this study was to evaluate the existence of
circulating cancer cells in patients with GIC to detect the presence of the same genetic
alterations in TP53, Ki-Ras2 and P16 in tissue and plasma.
Material and Methods: The analyses were performed on matched tumor tissue
and plasma obtained preoperative from 57 patients affected by CRC and 8
affected by Gastric cancer who underwent resective surgery, and plasma obtained
from 52 patients during the post-operative period. Besides the same analyses were
conducted on a third group of 37 healthy subjects as control. The analysis of
Ki-Ras2 and TP53 was performed using the PCR, SSCP techniques and sequencing, P16
methylation status was evaluated using MSP technique (Methylation Specific PCR).
Results: TP53 mutations were found both in the plasma and in the tissue in 9/65
(14%), in 13/65 (20%) only in the tissue and no mutations in both were found in
43/65 (48%). Ki-Ras2 gene was mutated, in 5/65 (8%), both in plasma and in tissue, in
22/65 (34%) subjects were not detected mutations in plasma but only in tissue and in
38/45 (58%) none of them. Methylation status of P16 was analyzed in 36 cases: in
9/36 (25%) P16 was methylated in the tissue, between them 4/9 were methylated also
in the plasma (44%). No alterations in TP53, Ki-Ras2 and P16 were found in the
control group.
Conclusion: The analyses of genetic alterations of the primary tumors can be an useful
tool to understand the possibility to have a metastating relapse and to obtain
informations suitable for a better treatment.
vi190 | gastrointestinal cancer Volume 18 | Supplement 6 | June 2007






/annonc/article-abstract/18/suppl_6/vi188/150293 by Biblioteca di Psicologia U
nipa user on 07 N
ovem
ber 2018
